MetaCap

Abivax SA (ABVX) vs Mirum Pharmaceuticals (MIRM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Abivax SA (ABVX) over the past year, gaining 35.5% versus a loss of 38.5%. Abivax SA is the larger company by market cap ($6.41 billion vs $6.28 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVX-38.55%MIRM+35.45%
+87%+21%-45%
Nov 21, 20251 yearNov 20, 2026
ABVX+781.93%MIRM+232.63%
+1727%+803%-120%
Oct 16, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVX versus MIRM key metrics
MetricABVXMIRM
Share price$73.20$96.13
Market cap$6.41B$6.28B
1-day change-9.24%+0.65%
YTD return-45.72%+21.70%
1-year return-38.55%+35.45%
5-year return—+616.85%
Forward P/E—300.41
EPS (TTM)$-6.08$-14.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$521.31M
Revenue growth (YoY)—+54.74%
Net income (latest FY)—$-23.36M
Operating margin—-4.25%
Net margin—-4.48%
52-week high$148.83$130.00
52-week low$62.70$63.23
Distance from 52-week high-50.82%-26.05%
Analyst consensusnonestrong_buy
Avg. price target upside+123.47%+64.06%
Average volume1.35M692.51K
Shares outstanding87.54M65.28M
Employees98470
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed ABVX by 74.0 percentage points over the past year.

About Abivax SA

ABVX stock →

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

ABVX vs MIRM FAQ

Which is bigger, Abivax SA or Mirum Pharmaceuticals?

Abivax SA (ABVX) is larger, with a market capitalization of $6.41B compared with $6.28B for Mirum Pharmaceuticals (MIRM).

Which stock has performed better over the past year, ABVX or MIRM?

MIRM returned +35.45% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.

Are Abivax SA and Mirum Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons